Hosted by Ralph Weichselbaum, MD, Chair of the Department of Radiation and Cellular Oncology, University of Chicago, this episode tackles the burgeoning world of radiopharmaceuticals and features two radiation oncologists: Jeff Michalski, MD, MBA, Washington University in St. Louis and president of ASTRO, and Freddy Escorcia, MD, PhD, National Cancer Institute and National Institutes of Health. They kick it off by giving background context on isotope therapy and the current data for these therapies in different malignancies, including an update into peptides and SBRT; provide commentary on how randomized controlled trials account for the complexities of radiopharmaceuticals in their design (especially pertaining to selection criteria and dosage); and share how a radiation department is structured and staffed to account for all patient needs, including a push for a novel patient-centered approach that involves the nuclear medicine department.
N/A
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
